The average age of disease onset is 5070 years old with men and women affected equally. efficacy of traditional cardioprotective medications in AAV. == Summary == There is a lack of evidence-based cardiovascular risk assessment tools and cardioprotective therapies in patients with AAV which should be addressed to improve long-term outcomes. Keywords:ANCA vasculitis, Cardiovascular disease == Introduction == Cardiovascular disease is defined by the World Health Organisation and European Heart Network as an umbrella term encompassing all disorders that affect the heart muscle and circulatory system [1,2]. These include, but are not limited to, coronary heart disease, cerebrovascular disease, and rheumatic heart disease. Cardiovascular disease Asenapine is the commonest noninfectious cause of death globally. Between Asenapine 1990 and 2019, the number of people dying annually of cardiovascular disease rose from 12.1 to 18.6 million worldwide [3]. Cardiovascular disease imposes a huge economic burden; it is reported to cost the European Union economy 210 billion Asenapine annually, equating to 8% of total healthcare expenditure [4]. Consequently, there is an increasingly urgent need to address the rising incidence of cardiovascular disease and to reduce its impact on both patients and healthcare services globally. Since its inception in 1948, the Framingham Heart Study has identified several cardiovascular risk factors including increasing age, smoking, hypertension, and diabetes mellitus [5]. More recent is the recognition that autoimmunity is also associated with elevated cardiovascular risk [6]. Anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a prototypic autoimmune disease. The impact of cardiovascular disease in AAV is significant. Indeed, it is now the major cause of death for patients with AAV over the longer term. [7]. In this article, we review the factors contributing to the increased rates of cardiovascular disease in AAV and the evidence base for modifying cardiovascular risk in this patient group. == Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis == AAV is a rare autoimmune disease characterised by inflammation of the small and medium blood vessels which leads to endothelial cell injury and end-organ damage [8]. It has an overall prevalence of approximately 400 per million people globally [8] and comprises a group of three separate, but overlapping, conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). All three are defined by a loss of tolerance to neutrophil granule proteins, typically either proteinase-3 (PR3) or myeloperoxidase (MPO) [9]. Whilst most patients have circulating autoantibodies to these leucocyte antigens, 510% of patients are ANCA-negative. The average age of disease onset is 5070 years old with men and Mouse monoclonal to CD35.CT11 reacts with CR1, the receptor for the complement component C3b /C4, composed of four different allotypes (160, 190, 220 and 150 kDa). CD35 antigen is expressed on erythrocytes, neutrophils, monocytes, B -lymphocytes and 10-15% of T -lymphocytes. CD35 is caTagorized as a regulator of complement avtivation. It binds complement components C3b and C4b, mediating phagocytosis by granulocytes and monocytes. Application: Removal and reduction of excessive amounts of complement fixing immune complexes in SLE and other auto-immune disorder women affected equally. There is significant geographical variation in the prevalence of GPA which is typically more common with increasing latitude. Additionally, the incidence of GPA is higher in populations of primarily European ancestry, whereas MPA is more common in East Asian populations [8]. AAV can be difficult to diagnose as the condition can affect any organ system and presenting symptoms can vary between patients. All three conditions share non-specific symptoms of chronic inflammation such as arthralgia, fatigue, myalgia, and weight loss. Organs that are commonly involved in AAV include the upper and lower respiratory tract, eyes, lungs, kidneys, and skin. GPA, MPA, and EGPA each have typical patterns of organ involvement although there Asenapine is significant phenotypic heterogeneity and overlap such that diagnostic classification can be challenging (Fig.1) [8]. In addition, these diseases can present with variable tempo including indolent presentations that are often associated with significant diagnostic delay through to rapidly progressive and fulminant presentations that may be life-threatening (e.g., pulmonary haemorrhage or rapidly progressive glomerulonephritis). Once a diagnosis of AAV is confirmed, the immediate goal of treatment is to rapidly suppress inflammation and limit organ damage with immunosuppressive therapies (remission induction) [12]. Once.